[Advances in the domain of HIV].
Solignac
M
M
D019380:Anti-HIV Agents / Q000097:blood / Q000134:cerebrospinal fluid / Q000494:pharmacology / Q000627:therapeutic use; D001769:Blood / Q000821:virology; D002219:Carbamates; D002555:Cerebrospinal Fluid / Q000821:virology; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005260:Female; D005663:Furans; D005835:Genitalia / Q000378:metabolism; D005838:Genotype; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000097:blood / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage* / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism / Q000493:pharmacokinetics; D008297:Male; D009154:Mutation; D010641:Phenotype; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D019438:Ritonavir / Q000008:administration & dosage* / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism / Q000493:pharmacokinetics; D013449:Sulfonamides / Q000097:blood / Q000134:cerebrospinal fluid / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D019562:Viral Load
D019380:Anti-HIV Agents; D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D019469:Indinavir; D019438:Ritonavir